Additional clinical endpoints, including reduction in disability progression, as measured by Expanded Disability Severity Scale (EDSS), were also achieved.
In the trial, Laquinimod was safe and well-tolerated.
In addition to the ongoing MS clinical studies, Laquinimod is currently in Phase II development for crohn’s disease and Lupus, and is being studied in other autoimmune diseases.
Principal investigator Giancarlo Comi said that this pivotal study met its primary endpoint while maintaining a very good safety profile.
"Laquinimod demonstrated a significant reduction in the progression of disability which may be explained by its unique mechanism of action that includes neuroprotective properties,"Comi said.